Blood and lung scans may reveal who benefits from biologics for severe ACOS
NCT ID NCT07602881
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will follow 500 people with severe eosinophilic asthma-COPD overlap syndrome (ACOS) who are starting treatment with a biologic drug (benralizumab, mepolizumab, or dupilumab). Researchers will analyze blood exosomes and lung imaging to find markers that predict which patients respond best. The goal is to build a model that helps doctors personalize treatment for better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose the right biologic for each patient with severe eosinophilic ACOS, improving treatment outcomes.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test new therapies, and the findings may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE EOSINOPHILIC ACOS (ASTHMA-COPD OVERLAP) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union hospital, Tongji Medical college, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China